Expressive Wealth LLC Takes Position in Johnson & Johnson $JNJ

Expressive Wealth LLC purchased a new stake in shares of Johnson & Johnson (NYSE:JNJ - Free Report) in the fourth quarter, according to the company in its most recent filing with the SEC. The firm purchased 4,545 shares of the company's stock, valued at approximately $941,000. Johnson & Johnson comprises approximately 1.0% of Expressive Wealth LLC's portfolio, making the stock its 24th biggest position.

A number of other large investors have also recently modified their holdings of JNJ. Brighton Jones LLC boosted its position in shares of Johnson & Johnson by 13.9% during the 4th quarter. Brighton Jones LLC now owns 51,876 shares of the company's stock valued at $7,502,000 after acquiring an additional 6,332 shares during the last quarter. United Bank grew its position in Johnson & Johnson by 110.7% during the first quarter. United Bank now owns 9,279 shares of the company's stock valued at $1,539,000 after acquiring an additional 4,876 shares during the last quarter. Sivia Capital Partners LLC raised its stake in shares of Johnson & Johnson by 13.4% during the second quarter. Sivia Capital Partners LLC now owns 5,863 shares of the company's stock worth $896,000 after acquiring an additional 692 shares in the last quarter. Wealth Group Ltd. lifted its holdings in shares of Johnson & Johnson by 12.8% in the 2nd quarter. Wealth Group Ltd. now owns 1,482 shares of the company's stock worth $226,000 after acquiring an additional 168 shares during the last quarter. Finally, Schnieders Capital Management LLC. lifted its holdings in shares of Johnson & Johnson by 9.8% in the 2nd quarter. Schnieders Capital Management LLC. now owns 73,680 shares of the company's stock worth $11,255,000 after acquiring an additional 6,584 shares during the last quarter. Institutional investors own 69.55% of the company's stock.

Johnson & Johnson Price Performance

Shares of Johnson & Johnson stock opened at $230.37 on Wednesday. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.03 and a quick ratio of 0.77. The business's 50 day simple moving average is $233.64 and its two-hundred day simple moving average is $224.19. The stock has a market capitalization of $554.55 billion, a P/E ratio of 26.63, a price-to-earnings-growth ratio of 2.29 and a beta of 0.27. Johnson & Johnson has a one year low of $149.04 and a one year high of $251.71.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last announced its quarterly earnings results on Tuesday, April 14th. The company reported $2.70 EPS for the quarter, topping analysts' consensus estimates of $2.68 by $0.02. Johnson & Johnson had a return on equity of 32.60% and a net margin of 21.83%.The business had revenue of $24.06 billion for the quarter, compared to analysts' expectations of $23.60 billion. During the same period in the previous year, the firm earned $2.77 EPS. The business's quarterly revenue was up 9.9% on a year-over-year basis. Johnson & Johnson has set its FY 2026 guidance at 11.450-11.650 EPS. Analysts forecast that Johnson & Johnson will post 11.57 EPS for the current year.

Johnson & Johnson Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, June 9th. Stockholders of record on Tuesday, May 26th will be paid a dividend of $1.34 per share. This represents a $5.36 annualized dividend and a dividend yield of 2.3%. This is a boost from Johnson & Johnson's previous quarterly dividend of $1.30. The ex-dividend date of this dividend is Tuesday, May 26th. Johnson & Johnson's payout ratio is presently 60.12%.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on JNJ shares. Weiss Ratings lowered shares of Johnson & Johnson from a "buy (b+)" rating to a "buy (b)" rating in a report on Friday, April 24th. Sanford C. Bernstein boosted their price objective on shares of Johnson & Johnson from $225.00 to $251.00 and gave the stock a "market perform" rating in a report on Wednesday, April 15th. JPMorgan Chase & Co. boosted their price objective on shares of Johnson & Johnson from $250.00 to $260.00 and gave the stock a "neutral" rating in a report on Wednesday, April 15th. Wall Street Zen lowered shares of Johnson & Johnson from a "buy" rating to a "hold" rating in a report on Saturday, February 14th. Finally, Barclays boosted their price objective on shares of Johnson & Johnson from $234.00 to $255.00 and gave the stock an "equal weight" rating in a report on Wednesday, April 15th. Twenty equities research analysts have rated the stock with a Buy rating and seven have assigned a Hold rating to the stock. According to data from MarketBeat, Johnson & Johnson has an average rating of "Moderate Buy" and a consensus target price of $253.04.

More Johnson & Johnson News

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: J&J’s DePuy Synthes unit announced an exclusive distribution agreement for the NOVOSIS bone graft substitute in the U.S., Canada and Australia, expanding its orthopedic portfolio and supporting MedTech growth. DePuy Synthes secures exclusive NOVOSIS bone graft distribution partnership (JNJ)
• Positive Sentiment: Multiple bullish articles highlighted J&J as a large-cap pharma stock to own as the industry shows signs of recovery, reinforcing investor confidence in its diversified pharma and MedTech mix. 4 Large-Cap Pharma Stocks to Buy as Industry Recovery Accelerates
• Positive Sentiment: Coverage also pointed to J&J’s strong dividend profile and “Dividend King” status, with the company’s long record of dividend growth supporting its appeal to income investors. Why Johnson & Johnson Might Be the Smartest Dividend King to Buy in Today's Market
• Neutral Sentiment: Market commentary noted healthcare stocks were a drag on the broader market, which can weigh on J&J even when company-specific news is constructive. Dow Gives Back Early Gains. Healthcare Stocks Are a Drag.
• Negative Sentiment: Fresh talc-litigation headlines remain a key overhang, including a Minnesota jury’s $10.2 million mesothelioma verdict tied to asbestos-contaminated cosmetic talc products. Assessing Johnson & Johnson (JNJ) Valuation After Guidance Raise Growth Initiatives And Talc Litigation Update
• Negative Sentiment: Broader concerns about potential drug-pricing pressure under President Trump could also limit pharma profit expectations, adding policy risk for J&J’s drug business. President Trump's Drug Pricing Policies Could Hurt Drugmakers' Profits. Time to Sell Pharma Stocks?

Johnson & Johnson Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company's pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.